ARCHIVES

As ImClone Investigation Continues, FDA Combines Drugs, Biologics Review; Memo Describes “Lengthy Process” That Led To FDA Decision; Oncology Community Praises FDA Move

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: NIH Budget Cut Being Considered, Threatening NCI’s Plan For Reaching Year 2000 Goals

December 13, 1984

Gene Delivery System Targets Tumor Blood Vessels In Dogs

March 27, 2009

RAC Grumbles, Gives Healy Guidelines For Compassionate Use Of Gene Therapy

January 22, 1993

Broder Hopes To Help “Fundable: Centers, Stops Short Of Promising Compliance With All IOM Points

May 5, 1989

FDA Needs Staff, Funds But first Must Determine Priorities, GAO Says

November 17, 1989

FDA Caps Advisors’ Holdings To $50,000 In Firms Affected By Committee Meetings.

August 8, 2008